Pitavastatin Reduces Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Ligands in Hypercholesterolemic Humans

[1]  Y. Kokubo,et al.  LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. , 2010, Clinical chemistry.

[2]  T. Sawamura,et al.  Lox-1: the multifunctional receptor underlying cardiovascular dysfunction. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[3]  Katsumi Miyauchi,et al.  Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin , 2009, Journal of the American College of Cardiology.

[4]  Børge G Nordestgaard,et al.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.

[5]  T. Sawamura,et al.  Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. , 2009, Clinical chemistry.

[6]  T. Kodama,et al.  Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). , 2008, Atherosclerosis.

[7]  K. Hirata,et al.  Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. , 2008, Journal of atherosclerosis and thrombosis.

[8]  T. Sawamura,et al.  Determination of LOX-1-ligand activity in mouse plasma with a chicken monoclonal antibody for ApoB. , 2008, Atherosclerosis.

[9]  G. Basta,et al.  Circulating Levels of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 are Associated with Inflammatory Markers , 2008, Lipids.

[10]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[11]  T. Sawamura,et al.  Antioxidants Suppress Plasma Levels of Lectinlike Oxidized Low-Density Lipoprotein Receptor-Ligands and Reduce Atherosclerosis in Watanabe Heritable Hyperlipidemic Rabbits , 2006, Journal of cardiovascular pharmacology.

[12]  T. Aoyama,et al.  A therapeutic dose of the lipophilic statin pitavastatin enhances oxidant-induced apoptosis in human vascular smooth muscle cells. , 2006, Journal of cardiovascular pharmacology.

[13]  J. Liao.  Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. , 2005, The American journal of cardiology.

[14]  Takeshi Kimura,et al.  Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome: A Novel Marker for Early Diagnosis , 2005, Circulation.

[15]  T. Sawamura,et al.  C-Reactive Protein Enhances LOX-1 Expression in Human Aortic Endothelial Cells: Relevance of LOX-1 to C-Reactive Protein–Induced Endothelial Dysfunction , 2004, Circulation research.

[16]  M. Horie,et al.  Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. , 2004, Journal of the American College of Cardiology.

[17]  E. Yeh,et al.  Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.

[18]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[19]  T. Sawamura,et al.  LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. , 2002, Pharmacology & therapeutics.

[20]  C. Sigmund,et al.  Macrophage-Specific Expression of Human Lipoprotein Lipase Accelerates Atherosclerosis in Transgenic Apolipoprotein E Knockout Mice but Not in C57BL/6 Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[21]  T. Matsuo,et al.  Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes , 2001, Circulation.

[22]  A. Iguchi,et al.  A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. , 2001, Atherosclerosis.

[23]  L. Lerman,et al.  Simvastatin Preserves Coronary Endothelial Function in Hypercholesterolemia in the Absence of Lipid Lowering , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[24]  T. Kita,et al.  Identification of soluble forms of lectin-like oxidized LDL receptor-1. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[25]  F. Werf,et al.  Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. , 1998, Circulation.

[26]  T. Kita,et al.  An endothelial receptor for oxidized low-density lipoprotein , 1997, Nature.

[27]  D. Steinberg,et al.  Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[29]  L. Stanton,et al.  CD36 is a receptor for oxidized low density lipoprotein. , 1993, The Journal of biological chemistry.

[30]  K. Kugiyama,et al.  Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins , 1990, Nature.

[31]  M. Freeman,et al.  Type I macrophage scavenger receptor contains α-helical and collagen-like coiled coils , 1990, Nature.

[32]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[33]  T. Yamashita,et al.  Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. , 2001, Atherosclerosis.

[34]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[35]  M. Freeman,et al.  Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. , 1990, Nature.